Kraken wrote: Thu May 25, 2023 11:49 pm
I got my Shingrex shots a year or two ago and was heartened by this news until I saw "We find strong protective effects of the vaccine for women but none for men".
Yeah, that's unfortunate. I noticed it as I was finishing posting, but I was too sleepy to alter my post.
The Self-Administered Gerocognitive Exam (SAGE) is designed to detect early signs of cognitive, memory or thinking impairments. It evaluates your thinking abilities and helps physicians to know how well your brain is working.
Well, in the spirit of "let's be able to have a little fun with each other" ...
I will share that many people report encounters and/or develop relationships with animals like rabbits, deer, or maybe raccoons; that begin to take on larger and larger roles in their world.
Update on the newly approved drug and how to get it:
The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai (4523.T) and Biogen's (BIIB.O) Leqembi for patients with Alzheimer's disease.
The FDA decision is expected to trigger broader coverage of the $26,500-a-year drug by the U.S. government's Medicare health plan for people aged 65 and older. Leqembi was granted "accelerated" FDA approval in January, but Medicare restricted coverage only to patients in clinical trials.
...
The FDA label for the drug says it should be started when patients are in the mild cognitive impairment or mild dementia stage of the degenerative brain disease.
The FDA recommends on Leqembi's label that doctors conduct testing for a gene called APOE4 that is associated with a higher risk of Alzheimer's as well as brain swelling associated with amyloid-lowering drugs. The FDA included a "boxed warning" that flags the risk of brain swelling on the label.
The agency does not require APOE4 genetic testing and doctors and patients will need to weigh the risk of brain swelling against the drug's potential benefits.
Around 25% of the population has one copy of the APOE4 gene, while up to 3% have two copies of the gene, according to the National Institute on Aging.
The FDA also warns that doctors should be particularly cautious when considering Leqembi for patients taking anticoagulants, which can also raise the risk of bleeding in the brain.
Eisai has estimated that the number of U.S. patients diagnosed with early Alzheimer's would total around 100,000 in Leqembi's first three years on the market.
Cindy and Deirdre are two great neighbors we've known for 20+ years. Yesterday Cindy texted my wife twice, first just "Help" and then "Stolen."
Obviously this was worrisome. We tried calling Cindy but got no answer. When we then called Deirdre, she told us that Cindy was in the early stages of Alzheimer's and that it was recently getting more serious.
Cindy is only 68, which is very young for the disease. She had a head injury in a car accident a couple of years ago, and I've heard that this can accelerate the onset.
The latest generation of anti-obesity drugs has taken the world by storm, thanks to their effectiveness at treating diabetes and reducing weight. But these drugs also have a less well-known superpower: the ability to suppress inflammation.
Evidence suggest that the drugs classified as GLP-1 receptor agonists — a category that includes brand names such as Mounjaro and Wegovy — can reduce inflammation in the liver, kidneys and heart. The drugs even seem to dial down inflammation in the brain, leading scientists to hope that the compounds could be used to treat Parkinson’s and Alzheimer’s diseases, both of which are characterized by brain inflammation. A recent review1 listed more than 20 clinical trials that are exploring the drugs as therapies for the two conditions.
Seems like those drugs should be in the water supply. But given that they're injections that aren't covered by insurance and stop working when you stop taking them, we've got a ways to go before we get there.
"A lie can run round the world before the truth has got its boots on." -Terry Pratchett, The Truth "The presence of those seeking the truth is infinitely to be preferred to those who think they've found it." -Terry Pratchett, Monstrous Regiment
Not once but twice I get to drop into this thread and post some (maybe) good news:
Novo Nordisk’s blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer’s disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday.
Semaglutide, the active ingredient in Ozempic, was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in patients with Type 2 diabetes compared with seven other diabetes medications. That includes insulin and older so-called GLP-1 drugs similar to Ozempic, the research said.
...
The results add to mounting evidence that GLP-1s, a popular class of obesity and diabetes medications, may offer health benefits beyond promoting weight loss and regulating blood sugar. That includes Ozempic, Novo Nordisk’s weight loss injection Wegovy, and drugs from Eli Lilly that work slightly differently
Needs additional studies to confirm, but that would be pretty impressive to establish.
How about cannabis? Has anyone considered it as a treatment? We live in the UK, and I found out about Releaf, a clinic that offers cannabis-based therapies for conditions like Alzheimer’s, and we think giving it a try.
Last edited by MCQueen2 on Sat Dec 14, 2024 3:51 pm, edited 2 times in total.
My wife assures me nobody suffers the long term effects of dementia in the Philippines thanks to a 100% effective treatment known as "
Ihulog ka sa bulkan."
Isgrimnur wrote: Fri Dec 06, 2024 2:32 pm
Jeff Vs. the Volcano.
My first to the Philippines visit she took me to Volcano Island in the middle of Taal Lake. She might have been setting me up even then. The condo we just closed on is about 30 miles away.
